Full Press Release Details
Appoints Elsy Boglioli to Executive Vice President, Strategy and
Corporate Development
Addition to Senior Leadership Team Brings to Cellectis In-Depth
Corporate Strategy Expertise within the Pharmaceutical and MedTech
NEW YORK--(BUSINESS WIRE)--December 4, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS),
a clinical-stage biopharmaceutical company focused on developing
immunotherapies based on gene-edited allogeneic CAR T-cells (UCART),
announced today that the Company has appointed Elsy Boglioli to the role
of Executive Vice President, Strategy and Corporate Development. Ms.
Boglioli's responsibilities include directing the long-term strategy and
current business priorities of Cellectis to ensure that the overall
mission of the Company is fulfilled. Ms. Boglioli joins Cellectis from
Boston Consulting Group (BCG), where she served as Partner and Managing
Director, and leader of BCG's biotech-focused business in Europe.
"Ms. Boglioli's extensive experience working with leading pharmaceutical
companies, along with her in-depth expertise on portfolio and innovation
strategies across the board, will be particularly vital for Cellectis as
we continue along the path to market for our game-changing allogeneic
CAR T-cell product candidates," said Dr. Andr Choulika, Cellectis CEO.
"We look forward to having her on board during this pivotal time in the
Company's history so that we can bring a transformative new type of
cancer care to patients in need across the globe as quickly and
efficiently as possible."
Ms. Boglioli has far-reaching expertise within the pharma and medtech
industries, focusing on everything from corporate strategy and M&A to
research. At BCG, she was also a member of the global biopharma
leadership team and global strategy practice management team and served
as regional head of the strategy practice for Europe.
"As off-the-shelf immunotherapies have such enormous potential to
advance cancer treatment today, I jumped at the chance to join
Cellectis, as the Company is not only developing a next-generation cure
for cancer, but it's also truly defining the future of care as we know
it today," added Ms. Boglioli. "This is all about creating products that
are both cost-effective and available to patients all over the world,
which will ultimately create a fundamental shift in how we approach
medicine moving forward."
Ms. Boglioli graduated from Ecole Polytechnique in Paris, France and
holds a master's degree in economy and management from Pompeu Fabra
University in Barcelona, Spain.
Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing - built on its flagship TALEN technology and
pioneering electroporation system PulseAgile - Cellectis uses the power
of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
owned by the Cellectis Group.
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risks factors that may affect company
business and financial performance, is included in filings Cellectis
makes with the Security Exchange Commission from time to time and its
financial reports. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
For further information, please contact:
Jennifer Moore, 917-580-1088
Caitlin Kasunich, 212-896-1241
Simon Harnest, 646-385-9008
Corporate Strategy and Finance